Regeneron Secures Sanofi-Aventis Antibody Funding Through 2017

Building on an existing partnership, Regeneron may receive as much as $1.3 billion from Sanofi-Aventis through 2017 with no obligation to repay.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet